James D. Lewis, MD, MSCE; Brian L. Strom, MD, MPH
Acknowledgments: The authors thank Gerald Faich, MD, MPH, and Peter Honig, MD, for their thoughtful review of an earlier version of this editorial.
Requests for Single Reprints: James D. Lewis, MD, MSCE, Center for Epidemiology and Biostatistics, University of Pennsylvania, 7th Floor Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021; e-mail, email@example.com.
Disclaimer: Dr. Lewis has served as a consultant for several pharmaceutical companies, including Bayer, Centocor, Wyeth, and McNeil. He has also had research funded by Bayer, Centocor, and Whitehall-Robins. He has consulted for Bayer on issues related to phenylpropanolamine, a component of LipoKinetix. Otherwise, none of the consulting or research was related to dietary supplements. Dr. Strom is funded for his research and has served as a consultant to most of the major pharmaceutical manufacturers. He has worked with Wyeth on issues related to fen/phen. He has also consulted with Whitehall on issues related to phenylpropanolamine, a component of LipoKinetix. Otherwise, he has not been a consultant to any supplement manufacturer or researched supplements per se, although some pharmaceutical manufacturers market supplements as well.
Current Author Addresses: Drs. Lewis and Strom: Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 7th Floor Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104.
Ann Intern Med. 2002; 136:616-618.
Lewis JD, Strom BL. Balancing Safety of Dietary Supplements with the Free Market. Ann Intern Med. 2002;136:616–618. doi: 10.7326/0003-4819-136-8-200204160-00011
Download citation file:
Published: Ann Intern Med. 2002;136(8):616-618.
Cardiology, Emergency Medicine, Gastroenterology/Hepatology, Liver Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use